Latest TRVI reports update at 2024-05-07: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Trevi Therapeutics TRVI

$ 2.57 -0.77%

Trevi Therapeutics Balance Sheet 2011-2024 | TRVI

Annual Balance Sheet Trevi Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-32.2 M	-12.6 M	-36.7 M	-31 M	-57 M	-17.2 M	-16.7 M	-	-	-	-	-	-
Long Term Debt	31 K	2 K	24 K	14 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	184 K	25 K	120 K	113 K	99 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	14.3 M	257 K	506 K	325 K	-	-	-	-	-	-
Total Current Liabilities	5.82 M	13.4 M	12.7 M	5.56 M	5.2 M	-	-	-	-	-	-	-	-
Total Liabilities	6.86 M	15.6 M	21.4 M	19.8 M	5.46 M	3.18 M	7.45 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-239 M	-210 M	-181 M	-147 M	-114 M	-109 M	-84.4 M	-	-	-	-	-	-
Total Assets	89.4 M	123 M	38.5 M	47.1 M	60 M	20.5 M	22.2 M	-	-	-	-	-	-
Cash and Cash Equivalents	32.4 M	12.6 M	36.8 M	45 M	57.3 M	7.2 M	-	-	-	-	-	-	-
Book Value	82.5 M	107 M	17.1 M	27.3 M	54.5 M	17.3 M	14.8 M	-	-	-	-	-	-
Total Shareholders Equity	82.5 M	107 M	17.1 M	27.3 M	54.5 M	-109 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Trevi Therapeutics

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	949 K	31 K	62 K	93 K	124 K	2 K	2 K	3 K	-	24 K	58 K	91 K	123 K	144 K	144 K	144 K	144 K	257 K	257 K	257 K	257 K	46 K	46 K	46 K	46 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	6.22 M	6.86 M	6.29 M	5.9 M	14.5 M	15.6 M	18.5 M	20.9 M	19.9 M	21.4 M	20.2 M	21.4 M	19.2 M	19.8 M	19.8 M	19.8 M	19.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-250 M	-239 M	-231 M	-224 M	-216 M	-210 M	-205 M	-196 M	-188 M	-181 M	-172 M	-165 M	-155 M	-147 M	-147 M	-147 M	-147 M	-114 M	-114 M	-114 M	-114 M	-109 M	-109 M	-109 M	-109 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	78.6 M	89.4 M	95.9 M	101 M	116 M	123 M	128 M	81.4 M	30.4 M	38.5 M	31.6 M	39.1 M	42.9 M	47.1 M	47.1 M	47.1 M	47.1 M	60 M	60 M	60 M	60 M	10.5 M	10.5 M	10.5 M	10.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	13.8 M	32.4 M	26 M	13.8 M	11.7 M	12.6 M	66.6 M	24.7 M	29.1 M	36.8 M	29.3 M	36.4 M	41.6 M	45 M	45 M	45 M	45 M	57.3 M	57.3 M	57.3 M	57.3 M	7.2 M	7.2 M	7.2 M	7.2 M	22 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	72.3 M	82.5 M	89.6 M	95.1 M	102 M	107 M	110 M	60.5 M	10.5 M	17.1 M	11.4 M	17.7 M	23.7 M	27.3 M	27.3 M	27.3 M	27.3 M	60 M	60 M	60 M	60 M	10.5 M	10.5 M	10.5 M	10.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	72.3 M	82.5 M	89.6 M	95.1 M	102 M	107 M	110 M	60.5 M	10.5 M	17.1 M	11.4 M	17.7 M	23.7 M	27.3 M	27.3 M	27.3 M	27.3 M	54.5 M	54.5 M	54.5 M	54.5 M	-109 M	-109 M	-109 M	-109 M	-84.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency